Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
1. A method for treating an individual addicted to cocaine and having a chymotrypsin deficiency, the method comprising administering to the individual a therapeutically effective amount of a pharmaceutical preparation that comprises digestive enzymes, whereby the cocaine addiction is treated.
2. The method of claim 1 , wherein the digestive enzymes comprise an amylase, a lipase, and a protease.
3. The method of claim 1 , wherein the digestive enzymes consist of an amylase, a lipase, and a protease.
4. The method of claim 1 , wherein the digestive enzymes are selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.
5. The method of claim 1 , wherein the pharmaceutical preparation is administered orally via a dosage formulation selected from the group consisting of a pill, a tablet, a capsule, a microcapsule, a mini-capsule, a time released capsule, a mini-tab, a sprinkle, and a combination thereof.
6. The method of claim 2 , wherein the digestive enzymes comprise the amylase, and wherein the amount of amylase in the pharmaceutical preparation ranges from 10,000 to 60,000 U.S.P. units/dose.
7. The method of claim 2 , wherein the digestive enzymes comprise the protease, and wherein the amount of protease in the pharmaceutical preparation ranges from 10,000 to 70,000 U.S.P. units/dose.
8. The method of claim 2 , wherein the digestive enzymes comprise the lipase, and wherein the amount of lipase in the pharmaceutical preparation ranges from 4,000 to 30,000 U.S.P. units/dose.
9. The method of claim 1 , wherein determination that the individual has the chymotrypsin deficiency comprises measuring a level of chymotrypsin in a stool sample obtained from the individual with enzymatic photospectrometry or a colorimetric method, and comparing the level of chymotrypsin present in the stool sample to a normal level of chymotrypsin.